Longitudinal trajectories of nutritional markers in patients with de novo Stage IV gastric cancer: a descriptive analysis using one-year survival as a reference.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
131 patients, 36 survived at the one-year timepoint (27.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings are descriptive and hypothesis-generating rather than predictive. Dynamic nutritional assessment may contribute to understanding patient trajectories in patients with advanced gastric cancer.
OpenAlex 토픽 ·
Nutrition and Health in Aging
Inflammatory Biomarkers in Disease Prognosis
Gastric Cancer Management and Outcomes
[PURPOSE] This study investigated patients whose initial diagnosis was de novo Stage IV gastric cancer, a population with extremely poor prognosis and limited evidence regarding how longitudinal nutri
- p-value p < .001
- p-value p = .026
APA
Yu-Xuan Peng, Yi-Chieh Tsai, Wen-Pei Chang (2026). Longitudinal trajectories of nutritional markers in patients with de novo Stage IV gastric cancer: a descriptive analysis using one-year survival as a reference.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10641-x
MLA
Yu-Xuan Peng, et al.. "Longitudinal trajectories of nutritional markers in patients with de novo Stage IV gastric cancer: a descriptive analysis using one-year survival as a reference.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol. 34, no. 4, 2026.
PMID
41927806 ↗
Abstract 한글 요약
[PURPOSE] This study investigated patients whose initial diagnosis was de novo Stage IV gastric cancer, a population with extremely poor prognosis and limited evidence regarding how longitudinal nutritional changes evolve over time in advanced disease. We examined the trajectories of hemoglobin (Hgb), body mass index (BMI), and the prognostic nutritional index (PNI) as well as descriptively explored differences in nutritional trajectories between survival-defined groups based on one-year survival.
[METHODS] A retrospective longitudinal study was conducted among patients with pathologically confirmed de novo Stage IV gastric adenocarcinoma at a medical center in Taiwan (2015-2024). Nutritional markers were collected at baseline and at 1, 2, 3, 6, and 9 months. Patients were descriptively grouped according to one-year overall survival, which was used solely as a post hoc analytic reference for exploratory comparative analyses of longitudinal nutritional trajectories. Between-group differences were tested using the Mann-Whitney U test, and generalized estimating equations were applied to evaluate group, time, and group × time effects.
[RESULTS] Among 131 patients, 36 survived at the one-year timepoint (27.5%). Baseline demographics and tumor characteristics did not differ between survival-defined groups. Non-survivors consistently had lower Hgb (baseline-6 months: all p < .001; 9 months: p = .026). BMI showed no baseline differences; however, significant group × time interactions emerged at 6 and 9 months. PNI was significantly lower in non-survivors at every time point (all p < .001) and showed significant interactions at 3, 6, and 9 months, reflecting a more pronounced longitudinal decline.
[CONCLUSION] In de novo Stage IV gastric cancer, differences in PNI and Hgb were evident between survival-defined groups from diagnosis onward, whereas BMI reflected nutritional deterioration only at later stages. Longitudinal changes in PNI observed to parallel evolving nutritional and systemic vulnerability. These findings are descriptive and hypothesis-generating rather than predictive. Dynamic nutritional assessment may contribute to understanding patient trajectories in patients with advanced gastric cancer.
[METHODS] A retrospective longitudinal study was conducted among patients with pathologically confirmed de novo Stage IV gastric adenocarcinoma at a medical center in Taiwan (2015-2024). Nutritional markers were collected at baseline and at 1, 2, 3, 6, and 9 months. Patients were descriptively grouped according to one-year overall survival, which was used solely as a post hoc analytic reference for exploratory comparative analyses of longitudinal nutritional trajectories. Between-group differences were tested using the Mann-Whitney U test, and generalized estimating equations were applied to evaluate group, time, and group × time effects.
[RESULTS] Among 131 patients, 36 survived at the one-year timepoint (27.5%). Baseline demographics and tumor characteristics did not differ between survival-defined groups. Non-survivors consistently had lower Hgb (baseline-6 months: all p < .001; 9 months: p = .026). BMI showed no baseline differences; however, significant group × time interactions emerged at 6 and 9 months. PNI was significantly lower in non-survivors at every time point (all p < .001) and showed significant interactions at 3, 6, and 9 months, reflecting a more pronounced longitudinal decline.
[CONCLUSION] In de novo Stage IV gastric cancer, differences in PNI and Hgb were evident between survival-defined groups from diagnosis onward, whereas BMI reflected nutritional deterioration only at later stages. Longitudinal changes in PNI observed to parallel evolving nutritional and systemic vulnerability. These findings are descriptive and hypothesis-generating rather than predictive. Dynamic nutritional assessment may contribute to understanding patient trajectories in patients with advanced gastric cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Stomach Neoplasms
- Female
- Male
- Longitudinal Studies
- Retrospective Studies
- Middle Aged
- Aged
- Body Mass Index
- Taiwan
- Nutritional Status
- Hemoglobins
- Neoplasm Staging
- Prognosis
- Nutrition Assessment
- Adenocarcinoma
- 80 and over
- Adult
- De novo Stage IV gastric cancer
- Hemoglobin
- Longitudinal trajectories
- Prognostic nutritional index
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.